Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIVE pre-HF Study
2024-512062-34-00Phase 2Completed
- Sponsor
- University College Dublin
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of empagliflozin in heart failure (HF), sponsored by University College Dublin. Primary endpoint: Change in LAVImax measured by CMR over 6 months. Started Mar 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2024-512062-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512062-34-00.